Zacks Investment Research upgraded shares of Mustang Bio (NASDAQ:MBIO) from a hold rating to a buy rating in a research report report published on Thursday morning. Zacks Investment Research currently has $12.00 target price on the stock.
According to Zacks, “Mustang Bio, Inc. a subsidiary of Fortress Biotech, Inc., is a clinical?stage biopharmaceutical company. It focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient’s own immune system to eliminate cancer cells. Mustang Bio, Inc. is based in New York, United States. “
A number of other research firms have also recently commented on MBIO. CIBC began coverage on Mustang Bio in a research report on Thursday, December 21st. They set an outperform rating and a $18.00 target price on the stock. Oppenheimer began coverage on Mustang Bio in a research report on Wednesday, December 20th. They set an outperform rating and a $18.00 target price on the stock.
NASDAQ:MBIO opened at $10.37 on Thursday. Mustang Bio has a 52 week low of $8.06 and a 52 week high of $13.35.
Several large investors have recently bought and sold shares of the company. Geode Capital Management LLC acquired a new stake in shares of Mustang Bio during the 4th quarter valued at about $639,000. Millennium Management LLC acquired a new stake in shares of Mustang Bio during the 4th quarter valued at about $326,000. Wells Fargo & Company MN acquired a new stake in shares of Mustang Bio during the 4th quarter valued at about $164,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Mustang Bio during the 4th quarter valued at about $131,000. Hedge funds and other institutional investors own 2.92% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Mustang Bio (MBIO) Rating Increased to Buy at Zacks Investment Research” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/mustang-bio-mbio-rating-increased-to-buy-at-zacks-investment-research.html.
Mustang Bio Company Profile
Mustang Bio, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market.
Get a free copy of the Zacks research report on Mustang Bio (MBIO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.